Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Operating Leases for 5 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 16.6% to $15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Dec 2025, down 16.6% year-over-year, with the annual reading at $15.8 million for FY2025, 16.6% down from the prior year.
  • Operating Leases for Q4 2025 was $15.8 million at 4D Molecular Therapeutics, down from $16.6 million in the prior quarter.
  • The five-year high for Operating Leases was $19.7 million in Q3 2024, with the low at $10.5 million in Q2 2024.
  • Average Operating Leases over 5 years is $14.6 million, with a median of $14.4 million recorded in 2022.
  • Peak annual rise in Operating Leases hit 65.93% in 2025, while the deepest fall reached 16.6% in 2025.
  • Over 5 years, Operating Leases stood at $15.2 million in 2021, then dropped by 11.49% to $13.5 million in 2022, then fell by 14.46% to $11.5 million in 2023, then soared by 64.63% to $19.0 million in 2024, then dropped by 16.6% to $15.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $15.8 million, $16.6 million, and $17.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.